On September 9, 2021 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, reported that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021 (Press release, Selecta Biosciences, SEP 9, 2021, View Source [SID1234587536]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021.

An archived webcast of the presentation will be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

On September 9 2021 Vyant Bio, Inc. ("Vyant Bio" or the "Company") (Nasdaq: VYNT), an emerging global drug discovery company, reported that it is rapidly identifying small and large molecule therapeutics to treat central nervous system ("CNS") and oncology-related diseases (Press release, Vyant Bio, SEP 9, 2021, View Source [SID1234587535]). Today, Vyant Bio announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Conference. The event is being held virtually from September 13-15, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Date: September 13-15, 2021 (Monday-Wednesday)
On-Demand Starts: 7:00 am ET – Monday, September 13, 2021
On-Demand Ends: 7:00 pm ET- Wednesday, September 15, 2021
Registration: View Source
Webcast: View Source
During the presentation, Vyant Bio’s Chief Executive Officer, Jay Roberts, will highlight the Company’s recent merger, integration with StemoniX, Inc. and the resulting transformational business strategy, noteworthy collaborations and partnerships, and the broader going-forward corporate vision. The presentation will be webcast and an archived recording will be made available in Investors’ section of the Vyant Bio website.

If you are an institutional investor and would like to attend the Company’s presentation, please click on the following link (View Source) to register for the H.C. Wainwright 23rd Annual Global Conference. Once your registration is confirmed, you will be prompted to log into the conference website and will be able to request a one-on-one meeting with the Company.

Vyant Bio will also be available for virtual outside 1:1 meetings both during and after the H.C. Wainwright 23rd Annual Global Conference. Please contact Jennifer K. Zimmons, Ph.D. at [email protected] or +1 917.214.3514 for scheduling.

On September 9, 2021 KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, reported that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021 (Press release, KemPharm, SEP 9, 2021, View Source [SID1234587534]). The prerecorded presentation will be available starting at 9:00 a.m., ET on September 13, 2021, and can be accessed via the conference’s virtual platform by registered conference attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Event: H.C. Wainwright 23rd Annual Global Investment Conference
Date: September 13-15, 2021
Time: Presentations available starting at 9:00 a.m., ET on September 13, 2021
Registration: View Source

On September 9, 2021 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, reported the Company’s CEO Dr. Pnina Fishman will present at the H.C. Wainwright 23rd Annual Global Investment Conference which will take place virtually on September 13 – 15, 2021 (Press release, Can-Fite BioPharma, SEP 9, 2021, View Source [SID1234587533]). Can-Fite’s presentation will be available starting at 7:00 AM ET on Monday, September 13 on the Healthcare and Biotech track at H.C. Wainright’s conference portal: link. Management will also conduct virtual 1×1 meetings with institutional investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 9, 2021 PharmaCyte Biotech presented Corporate presentation (Presentation, PharmaCyte Biotech, SEP 9, 2021, View Source [SID1234587523]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!